Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
For Oncodesign, artificial intelligence (AI) is not a goal, but rather a powerful technology to make drug discovery faster and more reliable.
AI is the technological pillar chosen by Oncodesign to generate its innovation and support its growth over the next 5 to 10 years. We are committed to bringing therapeutic innovation to patients at an ever faster pace.
The main objective of the Artificial Intelligence Business Unit is to develop a platform to identify and validate therapeutic targets. The therapeutic target is the cornerstone of Drug Discovery programs in Precision Medicine. This platform, created within Oncodesign, is strategic in order to fulfill its goals.
Our OncoSNIPER technology module
This technology platform was designed to identify signatures that can stratify populations of patients refractory to anticancer drugs. These signatures are then translated into therapeutic targetsby biologists in our laboratories.
a program to stratify and characterize patient populations refractory to cancer treatments.
Labcom Artificial Intelligence in Drug Discovery for Health (AIDD4H)
A joint laboratory, the AIDD4H "LabCom", is run in collaboration with the CIAD [French Distributed Knowledge and Artificial Intelligence laboratory] for an alliance of connectionist and symbolic AI technologies.
Our AI BU team is made up of highly qualified scientists with all the different expertise needed to mobilize artificial intelligence at every stage of the drug discovery process.Our activities rely on a team of data scientists, bioinformaticians, mathematicians, data hunter et architects, statisticians, biologists, pharmacologists, chemists,supported by the Oncodesign IT department to run a high-performance and secure storage and calculation infrastructure.
What gives this organization its strength is its robust connection on the ground with the experts present in Oncodesign’s Service and Biotech Business Units.